Will PMYAX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below. On Sept. 30, 2025 Putnam Investments announced that lead portfolio manager Gerard ...
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback